CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 74-771

Approval Letter

ANDA 74-771

JUL 9 1997

Baker Norton Pharmaceuticals, Inc.
Attention: Steven M. Viti, Ph.D.
4400 Biscayne Boulevard
Miami, FL 33137

Dear Sir:

This is in reference to your abbreviated new drug application dated October 20, 1995, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Cholestyramine for Oral Suspension, USP (equivalent to 4g resin/packet or scoopful).

Reference is also made to your amendments dated June 13, October 18, and November 27, 1996; and April 3, May 14, May 29 and July 1, 1997.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Cholestyramine for Oral Suspension USP to be bioequivalent and, therefore, therapeutically equivalent to that of the reference listed drug (Questran® Powder of Bristol Myers Squibb Co.).

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application is set forth in 21 CFR 314.80-81. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-240). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-240) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

/S/ 7/8/97

Douglas L. Sporn
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

ANDA 74-771

JUL 9 1997

Baker Norton Pharmaceuticals, Inc.
Attention: Steven M. Viti, Ph.D.
4400 Biscayne Boulevard
Miami, FL 33137

Dear Sir:

This is in reference to your abbreviated new drug application dated October 20, 1995, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Cholestyramine for Oral Suspension, USP (equivalent to 4g resin/packet or scoopful).

Reference is also made to your amendments dated June 13, October 18, and November 27, 1996; and April 3, May 14, May 29 and July 1, 1997.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Cholestyramine for Oral Suspension USP to be bioequivalent and, therefore, therapeutically equivalent to that of the reference listed drug (Questran® Powder of Bristol Myers Squibb Co.).

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application is set forth in 21 CFR 314.80-81. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-240). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-240) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

/S/

Douglas L. Sporn
Director
Office of Generic Drugs
Center for Drug Evaluation and Research